Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST Stock – (NASDAQ: ACST) is providing an update on the usage

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of its “at the market” equity providing plan.

As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering program under which Acasti may issue as well as sell from time to time its common shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being sold at prevailing market prices averaging US$1.0747 per share. No securities had been offered in the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with extra freedom in its ongoing review process to explore and evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescribed drugs using OM3 fatty acids delivered both as totally free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of efficacy as well as safety in lowering triglycerides in clients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for patients with severe HTG.

Forward Looking Statements – ACST Stock

Statements in this press release which aren’t statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, and other unknown variables that can cause the particular outcomes of Acasti to be materially different from historical success and as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, people are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the day of this press release. Forward-looking assertions in this press release include, but are not restricted to, statements or information concerning Acasti’s strategy, future operations as well as the review of its of strategic options.

The forward-looking claims contained in this specific press release are expressly qualified in their entirety by this cautionary statement, the “Special Note Regarding Forward Looking Statements” area in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor area of Acasti’s site at www.acastipharma.com. All forward looking statements in this press release are available as of the day of this particular press release.

ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a result of info which is brand new, future events or even otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to assumptions and risks as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is providing an update on the usage

Leave a Reply

Your email address will not be published. Required fields are marked *